<DOC>
	<DOCNO>NCT00005869</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . It yet know whether nitrocamptothecin effective gemcitabine pancreatic cancer . PURPOSE : Randomized phase III trial compare effectiveness nitrocamptothecin gemcitabine treat patient unresectable locally advanced metastatic pancreatic cancer .</brief_summary>
	<brief_title>Nitrocamptothecin Compared With Gemcitabine Treating Patients With Unresectable Locally Advanced Metastatic Pancreatic Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Compare overall survival , time treatment failure , clinical benefit response rate ( analgesic consumption , pain intensity , performance status , weight change ) , objective response rate chemotherapy-naive patient unresectable locally advanced metastatic adenocarcinoma pancreas treat oral nitrocamptothecin v gemcitabine . II . Compare toxicity 2 regimens patient . OUTLINE : This randomize , open-label , multicenter study . Patients stratify accord measurable disease ( yes v ) , Karnofsky performance status ( 50-70 % vs 70-100 % ) , prior radiotherapy . Patients randomize 1 2 treatment arm . Arm I : Patients receive oral nitrocamptothecin day 1-5 . Treatment repeat every week 8 course absence disease progression unacceptable toxicity . Patients stable respond disease week 8 may receive additional course . Arm II : Patients receive gemcitabine IV 30 minute day 1 . Treatment repeat every week 7 course absence disease progression unacceptable toxicity . Patients undergo 1 week rest . Patients stable respond disease week 8 may receive gemcitabine IV 30 minute day 1 , 8 , 15 . Courses repeat every 4 week . Pain assess within 7 day prior study , day 28 56 study , every 28 day completion study . Patients follow every 3 month 1 year death . PROJECTED ACCRUAL : Approximately 994 patient ( 497 per arm ) accrue study within 22 month .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Rubitecan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm unresectable locally advanced ( stage II III ) metastatic ( stage IV ) adenocarcinoma pancreas PATIENT CHARACTERISTICS : Age : Over 18 Performance status : Karnofsky 50100 % Life expectancy : Not specify Hematopoietic : Granulocyte count great 1,500/mm3 Hemoglobin least 9 g/dL Platelet count great 100,000/mm3 Hepatic : SGOT SGPT great 3 time normal ( 5 time normal liver tumor present ) Bilirubin great 2.0 mg/dL Renal : Creatinine great 2.0 mg/dL Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : At least 3 week since prior immunotherapy recover No filgrastim ( GCSF ) concurrent nitrocamptothecin Concurrent epoetin alfa allow Chemotherapy : Prior fluorouracil radiosensitizer allow No prior chemotherapy ( e.g. , nitrocamptothecin gemcitabine ) No concurrent chemotherapy Endocrine therapy : No concurrent hormonal corticosteroid therapy Patients require hormonal therapy corticosteroid therapy medical reason may remain study , evaluable clinical benefit response Radiotherapy : At least 3 week since prior radiotherapy recover No concurrent radiotherapy Surgery : See Disease Characteristics More 2 week since prior major surgery recover Prior stent placement allow No plan surgery within 8 week initiation treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2007</verification_date>
	<keyword>stage II pancreatic cancer</keyword>
	<keyword>stage III pancreatic cancer</keyword>
	<keyword>recurrent pancreatic cancer</keyword>
	<keyword>adenocarcinoma pancreas</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
</DOC>